Table S2. Subgroup meta-analysis of overall survival comparison between the younger group and older group.
| Subgroup | Included studies | Included patients | I2 (%) | Effect model | OR/WMD | 95% CI | P |
|---|---|---|---|---|---|---|---|
| OS | |||||||
| 1-year OS | 8 | 59,132 | 81 | Random | 1.08 | 0.80–1.45 | 0.63 |
| 2-year OS | 8 | 59,132 | 78 | Random | 1.04 | 0.79–1.36 | 0.79 |
| 3-year OS | 8 | 59,132 | 74 | Random | 1.01 | 0.78–1.32 | 0.93 |
| 5-year OS | 9 | 59,647 | 60 | Random | 1.01 | 0.79–1.30 | 0.92 |
| OS underwent gastrectomy | |||||||
| 1-year OS | 15 | 18,442 | 0 | Fixed | 1.20 | 1.04–1.39 | 0.01 |
| 2-year OS | 15 | 18,442 | 56 | Random | 1.31 | 1.08–1.58 | 0.005 |
| 3-year OS | 15 | 18,442 | 1 | Fixed | 1.33 | 1.19–1.48 | <0.001 |
| 5-year OS | 18 | 26,770 | 56 | Random | 1.35 | 1.16–1.57 | <0.001 |
| Stage I-OS underwent gastrectomy1 | |||||||
| 1-year OS | 5 | 5,437 | 0 | Fixed | 5.18 | 1.03–26.03 | 0.05 |
| 2-year OS | 5 | 5,437 | 0 | Fixed | 2.29 | 1.11–4.71 | 0.02 |
| 3-year OS | 5 | 5,437 | 0 | Fixed | 3.32 | 1.72–6.40 | <0.001 |
| 5-year OS | 8 | 6,536 | 11 | Fixed | 2.38 | 1.56–3.61 | <0.001 |
| Stage II-OS underwent gastrectomy | |||||||
| 1-year OS | 5 | 2,735 | 0 | Fixed | 1.54 | 0.72–3.33 | 0.27 |
| 2-year OS | 5 | 2,735 | 0 | Fixed | 1.25 | 0.80–1.94 | 0.33 |
| 3-year OS | 5 | 2,735 | 45 | Fixed | 1.47 | 1.01–2.14 | 0.04 |
| 5-year OS | 8 | 3,347 | 46 | Fixed | 1.28 | 0.98–1.66 | 0.07 |
| Stage III-OS underwent gastrectomy | |||||||
| 1-year OS | 5 | 4,499 | 61 | Random | 1.41 | 0.81–2.45 | 0.22 |
| 2-year OS | 5 | 4,499 | 55 | Random | 1.53 | 1.07–2.20 | 0.02 |
| 3-year OS | 5 | 4,499 | 60 | Random | 1.62 | 1.14–2.31 | 0.007 |
| 5-year OS | 7 | 5,702 | 27 | Fixed | 1.36 | 1.14–1.63 | <0.001 |
| Stage IV-OS underwent gastrectomy | |||||||
| 1-year OS | 5 | 1,341 | 74 | Random | 1.18 | 0.54–2.58 | 0.68 |
| 2-year OS | 5 | 1,341 | 83 | Random | 3.46 | 1.26–9.56 | 0.02 |
| 3-year OS | 5 | 1,341 | 41 | Fixed | 1.77 | 1.23–2.54 | 0.002 |
| 5-year OS | 7 | 1,483 | 0 | Fixed | 1.93 | 1.30–2.85 | 0.001 |
| OS underwent curative surgery | |||||||
| 1-year OS | 11 | 12,660 | 0 | Fixed | 1.35 | 1.05–1.72 | 0.02 |
| 2-year OS | 11 | 12,660 | 33 | Fixed | 1.22 | 1.03–1.45 | 0.02 |
| 3-year OS | 11 | 12,660 | 0 | Fixed | 1.36 | 1.17–1.58 | <0.001 |
| 5-year OS | 12 | 19,012 | 60 | Random | 1.39 | 1.12–1.72 | 0.002 |
| Stage I-OS underwent curative surgery | |||||||
| 5-year OS | 4 | 5,261 | 51 | Random | 1.73 | 0.86–3.49 | 0.13 |
| Stage II-OS underwent curative surgery | |||||||
| 5-year OS | 4 | 2,771 | 51 | Random | 1.07 | 0.80–1.43 | 0.67 |
| Stage III-OS underwent curative surgery | |||||||
| 5-year OS | 4 | 4,639 | 0 | Fixed | 1.29 | 1.05–1.58 | 0.01 |
| Stage IV-OS underwent curative surgery | |||||||
| 5-year OS | 3 | 1,016 | 0 | Fixed | 1.86 | 1.20–2.89 | 0.006 |
| OS underwent Non-curative surgery | |||||||
| 1-year OS | 3 | 268 | 70 | Random | 1.31 | 0.40–4.29 | 0.66 |
| 2-year OS | 3 | 268 | 38 | Fixed | 0.92 | 0.49–1.71 | 0.87 |
| 3-year OS | 3 | 268 | 0 | Fixed | 1.37 | 0.72–2.61 | 0.34 |
| 5-year OS | 3 | 268 | 0 | Fixed | 1.14 | 0.56–2.36 | 0.72 |
1stage, pTNM stage. OS, overall survival.